Study Phase 3

A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation

Trial Information

Generic NamePaliperidoneProduct NameINVEGA®Therapeutic AreaNervous System DiseasesEnrollment841% Female34%% White72.3%
Product ClassAtypical AntipsychoticsSponsor Protocol NumberR092670PSY3015Data PartnerJohnson & JohnsonCondition StudiedSchizophreniaMean/Median Age (Years)40.8

Supporting Documentation

  • Collected Datasets Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.